Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Agomelatine versus escitalopram for late-life depression
IRCT20130311012782N67Phase 3Recruiting
- Sponsor
- Isfahan University of Medical Sciences
- Start
- Aug 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in major depressive disorder (MDD) comparing Escitalopram arm with Agomelatine arm (2 arms). Primary endpoints: Severity of depressive symptoms, Severity of sleep disturbance and 1 more. Started Aug 2026; status: recruiting.
02
Drugs
agomelatineescitalopram
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on IRCT20130311012782N67.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20130311012782N67.